Morepen Laboratories Ltd Q4 FY2025 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/llckzo9gjb43kj6bbj7605c2.pdf

Key Takeaways


API: Volume Up, Price Down, and a Bottoming Call

Suri: "I think last 2 years were very interesting to note that China had collected lot of huge inventories during FY '22, '23. So they were sitting on the inventory. They had to sell up those inventories at any cost... But now they have liquidated everything. Now they are coming back with a normal costing."

Formulations & OTC: The B2C Pivot

Suri: "So instead of selling it to only B2B, where our value addition is only 30% to 40%. But if we make a tablet and capsule and go to market, then we get a better value-addition, maybe 60% to 70% value-addition."

Medical Devices: A Long Runway, Backed by Capacity


Resmetirom and the Pipeline Optionality


Margins: Compressed Now, with a Mix-Shift Remedy


Guidance & Commitments

CommitmentSpecificsTimeline
Quarterly revenue run-rateEvery quarter should touch ₹500 croresOngoing target
Capacity completionAll 600 KL of API capacity installed (514 KL already done)Within FY26
Medical representative hiringDouble field force from 200 to 400; appointments completedBy September 30, 2025
Medical representative ramp-upExpand to 750, then 1,200 over three yearsOver next 3 years
U.S. consumer launchLaunch medical devices on amazon.comNext quarter
Resmetirom bioequivalence studiesBegin studies once written protocol approval received from CDSCOUpon DCGI approval
Bempedoic acid commercial tractionExpect to deliver meaningful numbersComing 2-3 quarters
EBITDA and gross margin improvementBoth expected to improve as mix shifts toward formulations and devicesFiscal '26

Key Metrics

MetricQ4 FY25
Revenue₹470 cr, +10.1% YoY
FY25 revenue₹1,830 cr, +7.4% YoY
Pharma business revenue₹1,334 cr (FY25), +5.8% YoY; Q4 growth 8.5%
Medical devices revenue₹496 cr (FY25), +12% YoY; Q4 ₹103 cr, +15% YoY
EBITDA margin10.5% (FY25), +40 bps YoY; Q4 EBITDA declined
PAT growth+22% (FY25)
Export share of API72.1% (FY25), up from 67% in FY24
Export value₹700 cr (FY25), +26% over 3 years
API sales quantity476 tons (FY25), +57% vs FY23
API average selling price₹20,300 per kg, down 24% in 2 years from ₹26,000 per kg
New molecule contribution to API12.3% (FY25), up from 8% in FY22; ₹114 cr revenue
Formulation revenue₹344 cr (FY25), +21% over 2 years; Q4 finished dosage +29%
Glucometers installed base1.42 cr, +21% YoY
Test strips sold41.4 cr strips (FY25)
Glucometer and strips revenue₹387 cr (FY25)
BP monitor revenue growth+14% (FY25); units sold ~11 lakh, +12%
Medical devices EBITDA margin15% to 17%
U.S. exposure6% to 7% of total revenue
Capacity expansion target600 KL API capacity by FY26-end, from 314 KL; 514 KL installed
Medical representative target400 by Sep 2025, then 750, then 1,200; currently 200